Press release
Parkinson's Disease Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail
"Parkinson's Disease Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Parkinson's Disease Market.
The Parkinson's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Parkinson's Disease Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Parkinson's Disease treatment therapies with a considerable amount of success over the years.
*
Parkinson's Disease companies working in the treatment market are FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others, are developing therapies for the Parkinson's Disease treatment
*
Emerging Parkinson's Disease therapies in the different phases of clinical trials are- KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others are expected to have a significant impact on the Parkinson's Disease market in the coming years.
*
In June 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced its decision to advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson's disease. This move is based on findings from the Phase IIb PADOVA study and ongoing open-label extension (OLE) studies from both PADOVA and the earlier Phase II PASADENA trial.
*
In February 2025, AstraZeneca's diabetes drug Bydureon (exenatide) did not slow the progression of motor symptoms in Parkinson's disease during a Phase III trial. Led by University College London (UCL) in the UK, the Exenatide-PD3 trial (NCT04232969) aimed to assess the impact of the glucagon-like peptide 1 receptor agonist (GLP-1RA) on disease progression. However, results published in The Lancet revealed that the trial did not achieve its primary or secondary endpoints.
*
In January 2025, BlueRock Therapeutics, a U.S.-based subsidiary of Bayer, has advanced bemdaneprocel, its investigational cell therapy for Parkinson's disease, to Phase III trials following a Phase I study that demonstrated the treatment was well tolerated.
*
In January 2025, BIAL has announced the completion of the full dose regimen for the first participant in the multicenter Phase II ACTIVATE trial of BIA 28-6156, an allosteric activator of beta-glucocerebrosidase (GCase) for treating Parkinson's disease (PD). This therapy is specifically being developed for PD patients with a glucocerebrosidase 1 (GBA1) gene mutation (GBA-PD). Designed for once-daily oral administration, BIA 28-6156 aims to restore sphingolipid recycling to address the underlying cause of PD.
*
In December 2024, Belgian pharmaceutical company UCB decided to discontinue the development of minzasolmin for Parkinson's disease after the ORCHESTRA study did not achieve its primary or secondary endpoints. In the ORCHESTRA proof-of-concept trial (NCT04658186), minzasolmin-an investigational oral small-molecule inhibitor targeting alpha-synuclein misfolding-failed to show superiority over placebo.
*
In December 2024, Novotech, a leading global full-service clinical Contract Research Organization (CRO), released its latest report titled Parkinson's Disease: Global Clinical Trial Landscape 2024. The report provides valuable insights into current trends, key opportunities, and prevailing challenges in Parkinson's disease (PD) research, serving as an important resource for organizations developing therapies for this intricate neurodegenerative disorder.
Parkinson's Disease Overview
Parkinson's disease is a progressive nervous system disorder that affects movement. It develops when there is a gradual loss of certain nerve cells in the brain that produce dopamine, a chemical messenger responsible for smooth and coordinated muscle movements. As dopamine levels decrease, individuals with Parkinson's disease experience difficulties with movement control.
Get a Free Sample PDF Report to know more about Parkinson's Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights [https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Parkinson's Disease Drugs Under Different Phases of Clinical Development Include:
*
KM-819: FAScinate Therapeutics
*
Prasinezumab: Hoffmann-La Roche
*
P2B001: Pharma Two B Ltd.
*
NPT1220-478: Neuropore Therapies, Inc.
*
Dapansutrile: Olatec Therapeutics
*
UCB7853: UCB Biopharma
*
UB-312: Vaxxinity
*
Emrusolmin: Modag
*
PT320: Peptron
*
KDT-3594: Kissei Pharmaceutical
*
Tavapadon: Cerevel Therapeutics
Parkinson's Disease Route of Administration
Parkinson's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Inhalation
*
Inhalation/Intravenous/Oral
*
Intranasal
*
Intravenous
*
Intravenous/ Subcutaneous
*
NA
*
Oral
*
Oral/intranasal/subcutaneous
*
Parenteral
*
Subcutaneous
Parkinson's Disease Molecule Type
Parkinson's Disease Products have been categorized under various Molecule types, such as
*
Antibody
*
Antisense oligonucleotides
*
Immunotherapy
*
Monoclonal antibody
*
Peptides
*
Protein
*
Recombinant protein
*
Small molecule
*
Stem Cell
*
Vaccine
Parkinson's Disease Pipeline Therapeutics Assessment
*
Parkinson's Disease Assessment by Product Type
*
Parkinson's Disease By Stage and Product Type
*
Parkinson's Disease Assessment by Route of Administration
*
Parkinson's Disease By Stage and Route of Administration
*
Parkinson's Disease Assessment by Molecule Type
*
Parkinson's Disease by Stage and Molecule Type
DelveInsight's Parkinson's Disease Report covers around 100+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Parkinson's Disease product details are provided in the report. Download the Parkinson's Disease pipeline report to learn more about the emerging Parkinson's Disease therapies [https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Parkinson's Disease Therapeutics Market include:
Key companies developing therapies for Parkinson's Disease are - Pfizer Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Kissei Pharmaceutical Co., Ltd., AstraZeneca, Prevail Therapeutics, Amneal Pharmaceuticals LLC, AbbVie Inc., Viatris, Boehringer Ingelheim International GmbH, GSK plc, ABL bio, Teva Pharmaceuticals Industries Ltd, Newron Pharmaceuticals SPA, and others.
Parkinson's Disease Pipeline Analysis:
The Parkinson's Disease pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Parkinson's Disease with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's Disease Treatment.
*
Parkinson's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Parkinson's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Parkinson's Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Parkinson's Disease drugs and therapies [https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Parkinson's Disease Pipeline Market Drivers
*
Increasing prevalence of Parkinson's Disease patients, robust clinical-stage pipeline are some of the important factors that are fueling the Parkinson's Disease Market.
Parkinson's Disease Pipeline Market Barriers
*
However, lack of awareness and delayed diagnosis, side effects associated with Parkinson's disease treatment drugs and other factors are creating obstacles in the Parkinson's Disease Market growth.
Scope of Parkinson's Disease Pipeline Drug Insight
*
Coverage: Global
*
Key Parkinson's Disease Companies: FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others
*
Key Parkinson's Disease Therapies: KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others
*
Parkinson's Disease Therapeutic Assessment: Parkinson's Disease current marketed and Parkinson's Disease emerging therapies
*
Parkinson's Disease Market Dynamics: Parkinson's Disease market drivers and Parkinson's Disease market barriers
Request for Sample PDF Report for Parkinson's Disease Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Parkinson's Disease Report Introduction
2. Parkinson's Disease Executive Summary
3. Parkinson's Disease Overview
4. Parkinson's Disease- Analytical Perspective In-depth Commercial Assessment
5. Parkinson's Disease Pipeline Therapeutics
6. Parkinson's Disease Late Stage Products (Phase II/III)
7. Parkinson's Disease Mid Stage Products (Phase II)
8. Parkinson's Disease Early Stage Products (Phase I)
9. Parkinson's Disease Preclinical Stage Products
10. Parkinson's Disease Therapeutics Assessment
11. Parkinson's Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Parkinson's Disease Key Companies
14. Parkinson's Disease Key Products
15. Parkinson's Disease Unmet Needs
16 . Parkinson's Disease Market Drivers and Barriers
17. Parkinson's Disease Future Perspectives and Conclusion
18. Parkinson's Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=parkinsons-disease-pipeline-2025-moa-roa-fdaapproved-drugs-and-clinical-trial-progress-assessment-by-delveinsight-abbvie-pfizer-novartis-f-roche-kissei-pharma-astrazeneca-prevail]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail here
News-ID: 4152374 • Views: …
More Releases from ABNewswire
Global Green Building Materials Market to Hit USD 524.17 Billion by 2030 as Sust …
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2025-2030.
The construction industry is entering a pivotal phase as both consumers and businesses demand measurable environmental accountability. This shift is fueling the adoption of materials and design practices that lower a building's overall carbon and energy footprint. According to Arizton, the global green building materials market [https://www.arizton.com/market-reports/green-building-materials-market] was valued at USD 316.94 billion in 2024 and…
IBN Technologies Cyber Security Consulting Services Enable USA Companies to Stay …
IBN Tech delivers end-to-end cyber security consulting to help organizations identify vulnerabilities, strengthen defenses, and maintain audit readiness. Services include VAPT, SOC & SIEM consulting, MDR, vCISO advisory, and Microsoft cloud security management.
As the scale and sophistication of cyber threats continue to rise, organizations across industries face unprecedented difficulties in defending their digital infrastructures. Responding to this urgent need, IBN Tech offers robust cyber security consulting [https://www.ibntech.com/cybersecurity-maturity-assessment-services/] services, helping businesses…
Iceland Data Center Colocation Market Surpass USD 375 Million by 2030 as Smart C …
Insights on 8 Existing Colocation Data Center Facilities across Iceland.
According to Arizton's latest research, Iceland's data center colocation market [https://www.arizton.com/market-reports/iceland-data-center-colocation-market] is poised for robust expansion, projected to grow from USD 170 million in 2024 to USD 375 million by 2030, at a CAGR of 14.09%. The country currently hosts around seven operational colocation facilities, with several new developments in the pipeline. Backed by a stable digital ecosystem, abundant renewable energy,…
Civil Engineering Outsourcing by IBN Technologies Transforms Global Construction …
Civil engineering outsourcing is transforming project delivery by enabling faster design cycles, precise documentation, and cost optimization. The news highlights how IBN Technologies supports global construction firms through digital collaboration, skilled expertise, and regulatory compliance, helping organizations strengthen engineering performance and achieve sustainable growth.
As infrastructure projects grow in complexity, organizations are increasingly turning to civil engineering outsourcing [https://www.ibntech.com/real-estate-and-construction-engineering-services/] to manage costs, enhance design precision, and accelerate project delivery. Construction firms,…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
